



Figure S2


A.




B.



C.



D.



E.




Figure S2: *Effector function in MOSPD2-deficient myeloid cells.* (A) Purified TCR Tg CD4⁺ T cells specific for pOVA₃₂₃₋₃₃₉ were labelled with CFSE, co-cultured with monocytes isolated from wild-type (purple) or MOSPD2-deficient (red) mice, and activated for 72 hr in the presence of 0.1 µg/ml or 1 µg/ml peptide. CFSE dilution was analyzed by FACS. Each experiment was performed in triplicate. One of three experiments is shown. (B) OT-II T cells were co-cultured for 3 days with CD11b⁺ myeloid cells isolated from spleens of wild-type and MOSPD2 KO mice in the presence of the antigen at the indicated concentration and supernatants were tested for the indicated cytokines (n=5-6 per group). Results are mean ± SE. (C) Wild-type and MOSPD2 KO mice were immunized with pOVA₃₂₃₋₃₃₉ in CFA and 7-10 days later lymph nodes were excised. Cells were challenged for 3 days and then tested for proliferation by flow cytometry using Ki-67 (n=6 per group). Results are mean ± SE. (D) Whole blood from wild-type and MOSPD2 KO mice was treated to deplete RBC. Leukocytes were incubated with PE-labeled *E. coli* for 2 hr and the ratio of PE-labeled cells was measured. Results are on gated neutrophils based on SSC and FSC (n=5-6). Results are mean ± SE. (E) CD11b⁺ myeloid cells were isolated from spleens of wild-type and MOSPD2 KO mice in the presence of LPS (100 ng/ml) for 24 hr. Supernatants were collected and tested by ELISA for TNF-α and IL-6 (n=8 per group). Results are mean ± SE.